Literature DB >> 26570998

Pharmacogenomic agreement between two cancer cell line data sets.

.   

Abstract

Large cancer cell line collections broadly capture the genomic diversity of human cancers and provide valuable insight into anti-cancer drug response. Here we show substantial agreement and biological consilience between drug sensitivity measurements and their associated genomic predictors from two publicly available large-scale pharmacogenomics resources: The Cancer Cell Line Encyclopedia and the Genomics of Drug Sensitivity in Cancer databases.

Entities:  

Mesh:

Year:  2015        PMID: 26570998      PMCID: PMC6343827          DOI: 10.1038/nature15736

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  146 in total

1.  Computational Analyses Connect Small-Molecule Sensitivity to Cellular Features Using Large Panels of Cancer Cell Lines.

Authors:  Matthew G Rees; Brinton Seashore-Ludlow; Paul A Clemons
Journal:  Methods Mol Biol       Date:  2019

2.  The phosphatidylethanolamine biosynthesis pathway provides a new target for cancer chemotherapy.

Authors:  Yuan Guan; Xinyu Chen; Manhong Wu; Wan Zhu; Ahmed Arslan; Saori Takeda; Mindie H Nguyen; Ravindra Majeti; Dan Thomas; Ming Zheng; Gary Peltz
Journal:  J Hepatol       Date:  2019-11-22       Impact factor: 25.083

3.  Editing the immunopeptidome of melanoma cells using a potent inhibitor of endoplasmic reticulum aminopeptidase 1 (ERAP1).

Authors:  Despoina Koumantou; Eilon Barnea; Adrian Martin-Esteban; Zachary Maben; Athanasios Papakyriakou; Anastasia Mpakali; Paraskevi Kokkala; Harris Pratsinis; Dimitris Georgiadis; Lawrence J Stern; Arie Admon; Efstratios Stratikos
Journal:  Cancer Immunol Immunother       Date:  2019-06-20       Impact factor: 6.968

4.  Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays.

Authors:  Jun Li; Wei Zhao; Rehan Akbani; Wenbin Liu; Zhenlin Ju; Shiyun Ling; Christopher P Vellano; Paul Roebuck; Qinghua Yu; A Karina Eterovic; Lauren A Byers; Michael A Davies; Wanleng Deng; Y N Vashisht Gopal; Guo Chen; Erika M von Euw; Dennis Slamon; Dylan Conklin; John V Heymach; Adi F Gazdar; John D Minna; Jeffrey N Myers; Yiling Lu; Gordon B Mills; Han Liang
Journal:  Cancer Cell       Date:  2017-02-13       Impact factor: 31.743

5.  USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors.

Authors:  Kah Suan Lim; Heng Li; Emma A Roberts; Emily F Gaudiano; Connor Clairmont; Larissa Alina Sambel; Karthikeyan Ponnienselvan; Jessica C Liu; Chunyu Yang; David Kozono; Kalindi Parmar; Timur Yusufzai; Ning Zheng; Alan D D'Andrea
Journal:  Mol Cell       Date:  2018-12-20       Impact factor: 17.970

Review 6.  Genomic evolution of cancer models: perils and opportunities.

Authors:  Uri Ben-David; Rameen Beroukhim; Todd R Golub
Journal:  Nat Rev Cancer       Date:  2019-02       Impact factor: 60.716

Review 7.  Predictive approaches for drug combination discovery in cancer.

Authors:  Seyed Ali Madani Tonekaboni; Laleh Soltan Ghoraie; Venkata Satya Kumar Manem; Benjamin Haibe-Kains
Journal:  Brief Bioinform       Date:  2018-03-01       Impact factor: 11.622

8.  Safikhani et al. reply.

Authors:  Zhaleh Safikhani; Nehme El-Hachem; Petr Smirnov; Mark Freeman; Anna Goldenberg; Nicolai J Birkbak; Andrew H Beck; Hugo J W L Aerts; John Quackenbush; Benjamin Haibe-Kains
Journal:  Nature       Date:  2016-11-30       Impact factor: 49.962

9.  Integrative analysis of large-scale loss-of-function screens identifies robust cancer-associated genetic interactions.

Authors:  Christopher J Lord; Niall Quinn; Colm J Ryan
Journal:  Elife       Date:  2020-05-28       Impact factor: 8.140

10.  Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression.

Authors:  Timothy L Lochmann; Konstantinos V Floros; Mitra Naseri; Krista M Powell; Wade Cook; Ryan J March; Giovanna T Stein; Patricia Greninger; Yuki Kato Maves; Laura R Saunders; Scott J Dylla; Carlotta Costa; Sosipatros A Boikos; Joel D Leverson; Andrew J Souers; Geoffrey W Krystal; Hisashi Harada; Cyril H Benes; Anthony C Faber
Journal:  Clin Cancer Res       Date:  2017-11-08       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.